Literature DB >> 15356097

A novel epitope of N-CAM defines precursors of human adherent NK cells.

Shen Li1, Jun Xu, Valeria P Makarenkova, Tjendimin Tjandrawan, Jukka Vakkila, Torsten Reichert, William Gooding, Carl F Lagenaur, Cristian L Achim, William H Chambers, Ronald B Herberman, Theresa L Whiteside, Nikola L Vujanovic.   

Abstract

Activated, adherent natural killer (A-NK) cells represent a distinct subpopulation of interleukin (IL)-2-stimulated NK cells, which are selectively endowed with the increased expression of integrins and ability to adhere to solid surfaces, migrate into, infiltrate, and destroy cancerous tissues. The present study defines the phenotype and functions of precursors of A-NK (pre-A-NK) cells in humans. Peripheral blood pre-A-NK cells, in contrast to the rest of NK cells, express a novel epitope of CD56 neuronal cell adhesion molecule, termed ANK-1, and increased cell-surface levels of integrins. Pre-A-NK cells also express low levels of CD56 and CD161, and some express CD162 receptor, do not express CD25 or activation markers, and are effective mediators of NK cytotoxicity. Thus, pre-A-NK cells are generally similar to CD56(dim) NK cells. However, pre-A-NK cells differ from the main NK cell subpopulation by having a lower expression level of CD16 and a lower ability to mediate redirected antibody-dependent, cell-mediated cytotoxicity. More importantly, pre-A-NK cells are preferentially endowed with the ability to rapidly respond to IL-2 by integrin-mediated adherence to endothelial cells, extracellular matrix, and plastic. This early, specific response of pre-A-NK cells to IL-2 is followed by their activation, vigorous proliferation, and differentiation into phenotypically and functionally similar A-NK cells. Pre-A-NK cells represent only approximately 26% of peripheral blood NK cells but encompass the majority of NK cells in normal and cancerous, solid tissues. We conclude that pre-A-NK cells represent a distinct subset of resting, mature NK cells with the characteristics indicative of their ability to migrate and reside in solid tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356097     DOI: 10.1189/jlb.0802386

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

1.  The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer.

Authors:  Aaron S Mansfield; Paivi Heikkila; Karl von Smitten; Jukka Vakkila; Marjut Leidenius
Journal:  Virchows Arch       Date:  2012-11-13       Impact factor: 4.064

Review 2.  Role of TNF superfamily ligands in innate immunity.

Authors:  Nikola L Vujanovic
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

3.  Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk.

Authors:  Jun Xu; Ayan K Chakrabarti; Jennifer L Tan; Lisheng Ge; Andrea Gambotto; Nikola L Vujanovic
Journal:  Blood       Date:  2006-12-12       Impact factor: 22.113

4.  Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.

Authors:  Lazar Vujanovic; Wenners Ballard; Stephen H Thorne; Nikola L Vujanovic; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

5.  In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma.

Authors:  Lina Matera; Alessandra Galetto; Marilena Bello; Cinzia Baiocco; Isabella Chiappino; Giancarlo Castellano; Alessandra Stacchini; Maria A Satolli; Michele Mele; Sergio Sandrucci; Antonio Mussa; Gianni Bisi; Theresa L Whiteside
Journal:  J Transl Med       Date:  2006-11-14       Impact factor: 5.531

6.  CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.

Authors:  Lazar Vujanovic; Christopher Chuckran; Yan Lin; Fei Ding; Cindy A Sander; Patricia M Santos; Joel Lohr; Afshin Mashadi-Hossein; Sarah Warren; Andy White; Alan Huang; John M Kirkwood; Lisa H Butterfield
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.